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Abstract
Objective: Atypical forms of hyperthyroidism represent a diagnostic challenge for clinicians. Struma
ovarii is an ovarian teratoma and constitutes a rare cause of ectopic thyroidal hormonal production.
We describe a case of struma ovarii that combined two different sources of hyperthyroidism in the
same patient and report genetic studies in order to contribute a better understanding of the autonomy
and tumorigenesis of the struma ovarii.
Case report: A 73-year-old nulliparous woman presented a thyroid toxic adenoma that was success-
fully treated with 10 mCi radioiodine. Unexpectedly, a new onset of hyperthyroidism prompted us
to look for a second etiology. A whole-body scan with 123I detected a pelvic hyperfixation suggesting
struma ovarii, and a thyroid differentiated left ovarian teratoma 3 cm in size was surgically removed.
We screened for mutations of thyroid-stimulating hormone receptor and Gs-a protein genes, as these
mutations are common in thyroid adenomas. We did not identify any mutations. Androgen receptor
study demonstrated a monoclonal status. Comparative genomic hybridization did not reveal any chro-
mosomal abnormality. However, loss of heterozygosity analysis showed several structural abnormal-
ities, compared with the majority of benign ovarian teratomas, which show a normal karyotype.
Conclusions: This is the first well-documented report of thyrotoxic struma ovarii revealed after treat-
ment of a single thyroid toxic adenoma. We have shown in this case that struma ovarii originates
from a single germ cell, and, albeit benign, this tumor presents several chromosomal abnormalities.
Struma ovarii-induced hyperthyroidism is likely to be mediated by mechanisms different from those of
the classical thyroid toxic adenoma.
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Introduction
Thyrotoxicosis is commonly caused by excessive pro-
duction of thyroid hormones by the thyroid gland, as
in Graves’ disease, toxic adenoma or toxic multinodular
goiter. These and other causes of hyperthyroidism as
well are associated with a high 24-h radioiodine
uptake (RAI) in the thyroid bed. In contrast, some
other causes of thyrotoxicosis are associated with a
low 24-h RAI and are classified as atypical forms of
hyperthyroidism. These latter represent a diagnostic
puzzle for clinicians and may delay a proper manage-
ment (1). As summarized in Table 1, atypical hyperthyr-
oidism includes thyroid inflammation, iodine-induced
hyperthyroidism and/or ectopic secretion of thyroid
hormones.
Struma ovarii is a rare, mature ovarian teratoma.
Since its first description in 1889, approximately 500
cases have been reported; only 5–15% are complicated
by hyperthyroidism (2). Besides its rarity, the genotypic
features of mature ovarian teratoma are disputed
(3, 4), and the mechanisms underlying hyperthyroid-
ism caused by struma ovarii are still largely unknown.
We report here a woman with atypical hyperthyroid-
ism due to struma ovarii, co-existing with another
source of typical hyperthyroidism. A genetic study of
this teratoma was carried out to clarify its autonomy
and tumorigenesis.
Case report
A 73-year-old, nulliparous, Caucasian woman had suf-
fered a new onset of palpitations, tachycardia and a
weight loss of 14 kg during the year before admission.
Physical examination revealed a tender nodule 2 cm in
size in the right thyroid lobe. Laboratory findings were
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as follows: thyroid-stimulating hormone (TSH) , 0.01
mU/ml (0.1 –4.0), free thyroxine (FT4) ¼ 2.7 ng/ml
(0.7–2) and free triiodothyronine (FT3) ¼ 5 pg/ml
(1.5–5.5), with thyroglobulin antibodies (AbTg), thyro-
peroxidase antibodies (AbTPO), TSH-receptor antibodies
(TRAb), thyroglobulin and calcitonin in the normal
range. A 13 £ 8 £ 15 mm cervical nodule at ultrasono-
graphy showed intense 123I uptake. Hypothyroidism
was achieved 3 months later after 10 mCi 131I treat-
ment, and levothyroxine replacement was started pro-
gressively at a dose of 75mg daily. However, the
patient developed tachycardia and biochemically
detected hyperthyroidism, prompting us to re-evaluate
the thyroid profile without levothyroxine (TSH , 0.01
mU/ml, FT4 ¼ 2.5 ng/ml, FT3 ¼ 3 pg/ml, with AbTg,
AbTPO and TRAb in the normal range) on the hypoth-
esis of a residue of toxic adenoma, but a new RAI
showed ,1% uptake in the cervical tract. Since the
patient had high consumption of marine salt, a low-
salt diet was initiated. One month later, the urinary
iodine level was normal, but hyperthyroidism persisted.
Therefore, a whole-body scan with 123I was performed
to detect atypical hyperthyroidism. Intense tracer
activity was detected in the pelvis. An abdominal radio-
graph in the planar view demonstrated a pelvic soft
tissue density containing calcification; ultrasonography
of this region revealed a 12 £ 8 cm mass, containing
both solid and cystic components, located in the left
side. No hypervascularization was found by Doppler
ultrasound. Magnetic resonance imaging (MRI) of this
lesion showed a biloculated mass in T1-weighted
images; the solid part of the tumor was heterogeneous
and hyperintense in T2-weighted images.
The mass, originating in the left ovary and firmly
affixed to the rectosigmoid, was surgically removed.
Total anexohysterectomy and partial resection of the
sigmoid were performed (Fig. 1). Two weeks postopera-
tively, TSH had risen to 8mU/ml and FT4 was
1.2 ng/ml. A control whole-body iodine scan showed
a cervical residual uptake. Five years later, the patient
was free of symptoms and was receiving replacement
therapy with 87.5mg of levothyroxine.
Pathologic studies
Histology revealed brown thyroid tissue associated with
respiratory epithelium and bone tissue. Thyroid tissue
measured 2.5 £ 2.5 £ 3 cm. Thyroid follicles varied in
size with small and medium follicles consisted of cubic
epithelium surrounding colloid material that stained
positively with thyroglobulin but negatively with calci-
tonin. Fibroinflammatory cells and moderate cyto-
plasmic vacuolization suggested secondary effects of
the radioiodine treatment (Fig. 1). Teratoma tissue
was immediately stored at 270 8C for genetic studies.
Genetic investigations
1-TSH receptor and Gs-a subunit mutational
studies
Genomic DNA and RNA were isolated from the
patient’s lymphocytes and tumor. DNA and RNA were
analyzed by PCR and RT-PCR respectively and
submitted to direct sequencing by standard protocols,
to detect either a known germinal or somatic
mutation of the receptor of TSH (TSHR) and Gs-a
subunit genes.
PCR products were purified and sequenced using the
Big Dye cycle sequencing kit (Applied Biosystem, Foster
City, CA, USA), and products of sequencing were ana-
lyzed on a 377 or 3100 Genetic Analyser (Applied Bio-
system). Mutations were investigated using Factura and
Sequence Navigator software.
TSH receptor gene The human TSHR gene is located
on chromosome 14q31 (distal position). Most of its
known activating mutations are located in exons 9
and 10 (from residue 430 to codon stop). Exon 9 was
amplified using intronic primers for genomic DNA, as
previously described (5), and exonic primers for cDNA




Factitious ingestion of thyroid hormone
Metastatic functional thyroid cancer
Iodine-induced hyperthyroidism
Figure 1 A: Anexohysterectomy and partial resection of sigmoid.
B: Magnification of struma ovary arising from left ovary. C: Histo-
logic examination of struma ovarii (staining type haematoxylin-
eosin; magnification 40 £ ). The thyroid follicles ( ) varied in size,
with middle and small follicles consisted of cubic epithelium
surrounding colloid material staining for thyroglobulin, but not for
calcitonin. Fibroinflammatory cells ( ) and moderate cyto-
plasmic vacuolization suggested secondary effects to radioiodine
treatment.
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(primer direct 5 0TGT AAA ACG ACG GCC AGT CGA GCT
TGC TGG ACG TGT CT30, the underlined sequence cor-
responding to universal primer M13D; primer reverse
50CAG TTT GTA GTG ACT AGT GAG GAG AAT
AAG30). Region 430-stop of exon 10 was amplified
using three fragments, as previously described (6). No
mutations were found, but a polymorphism, D727E,
was identified in the heterozygote state in both the
struma ovarii and the lymphocytes.
Gs-a gene The Gs-a gene is localized on chromosome
20q13 (distal position). Exons 8 and 9 were amplified
by PCR using intronic primers for genomic DNA, as pre-
viously described (7), and exonic primers for cDNA
(primer direct 50 ACT ATG TGC CGA GCG ATC AG 30;
primer reverse 50 CCC GGA TGA CCA TGT TGT AG
30). No mutations could be detected.
2-Monoclonality studies
The androgen receptor (AR) gene is mapped to chromo-
some Xq11.2–q12 (centromeric position).The human
AR gene assay (HUMARA) for the analysis of clonality
in tissue from female patients examines the inactivation
pattern of this gene on the X chromosome. This method
relies on the length polymorphism of a human AR gene
exon, which has restriction sites for methylase-sensitive
enzymes (HpaII). Only methylated inactive alleles
are preserved after HpaII digestion, and they are
amplified by PCR. If the subject is heterozygote at the
HUMARA after HpaII digestion, displaying two different
alleles would indicate polyclonal origin, whereas the dis-
playing of only one allele would indicate monoclonality.
The allele pattern of AR was compared in the patient’s
tumoral and lymphocytes DNA, as previously described
(8). In our case, digestion by HpaII has not been
necessary because, by HUMARA PCR amplification of
undigested samples, we found a loss of heterozygosity
for the AR gene in the tumor tissue, a clear sign of
monoclonality (Fig. 2).
3-Comparative genomic hybridization (CGH)
High molecular weight DNA was extracted from the
fresh frozen tumor using standard methods. CGH was
performed as previously described (9). Briefly, tumor
DNA was labeled with FITC-12-dUTP (DuPont,
Boston, MA, USA) by nick translation, and normal
reference DNA was labeled with Spectrum Red (Vysis
Inc., Downers Grove, IL, USA). Tumor and reference
DNAs were mixed with unlabeled Cot-1 DNA (Gibco
Invitrogen, Inc., Carlsbad, CA, USA), denatured and
applied on to denatured metaphase slides of normal
lymphocytes (Vysis Inc.). After hybridization at 37 8C
for 48 h, the slides were washed in 0.4 £ SSC/0.3%
NP-40 at 74 8C for 2 min and in 2 £ SSC/0.1% NP-40
at room temperature for 1 min. After air-drying, the
slides were counterstained with 0.1mg/ml 4,6-diami-
dino-2-phenylindole (DAPI) (Sigma) in an antifade sol-
ution (Vectashield, Vector Inc., Burlingame, CA, USA).
A control hybridization was also performed using
normal female DNA against normal male DNA.
Ten tri-color digital images (DAPI, Applied Spectral
Imaging, Carlsbad, CA, USA; FITC and Spectrum Red
fluorescence Vysis Inc., Downers Grove, IL, USA) were
collected from each hybridization using a Zeiss Axioplan
2 (Carl Zeiss Jena GmbH, Jena, Germany) epifluores-
cence microscope and a Sensys (Photometrics, Tucson,
Figure 2 HUMARA PCR amplification of
undigested samples showing LOH for
the AR gene in struma ovarii. N is the
matched normal tissue and T is the
tumor tissue.
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AZ, USA) charge-coupled-device camera interfaced to an
IPLab Spectrum 10 workstation (Signal Analytics Cor-
poration, Vienna, VA, USA). Relative DNA sequence
copy number changes were detected by analyzing the
fluorescence intensities of tumor and normal DNAs
along the length of all chromosomes in each metaphase
spread. The absolute fluorescence intensities were
normalized so that the average green-to-red ratio of all
chromosomes in each metaphase was 1.0. The final
results were plotted as a series of green-to-red ratio pro-
files and corresponding standard deviations (S.D.) for
each human chromosome from p-telomere to q-telo-
mere. At least 12 ratio profiles were averaged for each
chromosome to reduce noise. Green-to-red ratios over
1.20 were considered as gains of genetic material, and
ratios under 0.80 as losses. Heterochromatic regions,
the short arm of the acrocentric chromosomes and
chromosome Y were not included in the evaluation.
We did not find any chromosomal abnormalities in
the tumor.
4-Loss of heterozygosity (LOH) analysis
We further analyzed the tumor and normal tissues for
loss of heterozygosity (LOH). One, two or three microsa-
tellite markers, preferably one from the short (p) arm
and another from the long (q) arm, were chosen from
ABI Prism Linkage Mapping Set v. 2 (Applied Biosys-
tems, Foster City, CA, USA) for each chromosome:
D1S2667, D1S498, D1S249, D2S168, D2S112,
D3S1289, D3S1271, D4S391, D4S413, D5S630,
D5S436, D6S470, D6S262, D7S513, D7S640,
D8S550, D8S284, D9S286, D9S1776, D11S1338,
D11S925, D12S99, D12S86, D13S175, D13S170,
D14S283, D14S68, D15S165, D15S127, D16S404,
D16S515, D17S831, D17S798, D17S949, D18S452,
Figure 3 Electrophero-
grams showing LOH in
struma ovarii. LOH values
were calculated from the
height of the major peak of




DXS1227 are located at
7q33, 10q11.23, 10q23.1,
Xq21.32 and Xq27.2
respectively. N is the
matched normal tissue and
T is the tumor tissue.
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D18S61, D19S209, D19S884, D19S571, D20S889,
D20S196, D21S914 and D22S283. For chromosomes
10 and X, we used D10S547, D10S1653, D10S548,
D10S197, D10S208, D10S196, D10S1652,
D10S537, D10S1686, D10S185 and D10S192; and
DXS1060, DXS8051, DXS987, DXS1226, DXS1214,
DXS1068, DXS993, DXS991, DXS986, DXS990,
DXS1106, DXS8055, DXS1001, DXS1047, DXS1227,
DXS8043, DXS8091 and DXS1073, respectively. PCR
was performed in a 7.5ml reaction volume containing
0.17mM each of HEX-labeled forward and unlabeled
reverse primer (Invitrogen, Carlsbad, CA, USA), 4 mM
MgCl2, 0.3 units AmpliTaq Gold polymerase and
1 £ buffer II (Applied Biosystems), 250mM dNTPs
(Invitrogen), and 15 ng of genomic DNA. Amplification
was performed in a DNA Engine Tetrad (MJ Research,
Incline Village, NV, USA) with an initial denaturation
of 95 8C for 10 min, followed by 10 cycles of 94 8C for
15 s, 55 8C for 15 s and 72 8C for 30 s; 20 cycles of
89 8C for 15 s, 55 8C for 15 s and 72 8C for 30 s; and a
final extension at 72 8C for 10 min. A volume of 1ml
of each amplicon was added to 10ml of Hi-Di forma-
mide (Applied Biosystems) and 0.2ml of ROX 400HD
size standard (Applied Biosystems), denatured at 95 8C
for 5 min and loaded into an ABI Prism 3700 Genetic
Analyser (Applied Biosystems). LOH was assessed
using Genescan v. 3.7 and Genotyper v. 3.7 software
(Applied Biosystems). LOH was defined according to
the following formula: LOH index ¼ (T2/T1)/(N2/N1),
where T was the tumor sample, N was the matched
normal sample, and 1 and 2 were the intensities
of smaller and larger alleles respectively. If the ratio
was under 0.67 or over 1.3, the result was determined
to be LOH. We found LOH at 4p15.2 (D4S391),
7p21.3 –7q33 (D7S513, D7S640), 10q11.23
(D10S196), 10q23.1 (D10S1686), 13q12.11
(D13S175), 14q11.2 (D14S283), 16q23.1
(D16S515), Xp22.1–Xq21.32 (DXS1226, DXS991,
DXS986, DXS990) and Xq27.2 (DXS1227) (Fig. 3).
Discussion
Struma ovarii is a rare ovarian teratoma that consists
mainly of thyroid tissue, biologically and microscopi-
cally identical to normal thyroid (10).
Benign and malignant, struma ovarii represent
0.3 –1% of all ovarian neoplasms and 2–4% of all ovar-
ian teratomas (1, 2). Most patients are diagnosed
because of an ascitic syndrome or a pelvic tumoral
mass, whereas hyperthyroidism, with low radioiodine
uptake in the thyroid bed, is present in only about
5 –15% of cases (2, 11, 12).
The case we report has the peculiarity of involving
two different mechanisms of hyperthyroidism. The
first mechanism is the occurrence of a toxic thyroid
adenoma, according to ultrasonographic and scinti-
graphic evidence of a hot nodule, confirmed by
transient hypothyroidism and a blunted cervical
scintigraphy after radioiodine treatment. Second, unex-
pectedly, we found thyrotoxicosis of new onset due to
atypical hyperthyroidism, as demonstrated by a
whole-body scan with 123I, clearly depicting a pelvic
uptake suggestive of an ectopic source of thyroid hor-
mone production. Pelvic ultrasonography and MRI
detected a cystic mass 12 cm in diameter, and specific
pathologic examination identified a restraint mass,
3 cm in size, containing thyroid tissue.
The synchronous presentation of thyroid toxic ade-
noma and struma ovarii is an extremely rare condition.
Two previous cases of struma ovarii described in a
series of 25 patients were diagnosed after thyroidec-
tomy for Plummer’s disease (11). Nevertheless, these
cases were diagnosed before 1970, and the contri-
bution of teratomas to the thyrotoxic state seems diffi-
cult to assess retrospectively (13). The coexistence of
struma ovarii and Graves’ disease has rarely been
described (14).
As previously stated, struma ovarii has been found to
be biochemically and histologically identical to the
thyroid tissue. This case also suggests that hyperfunc-
tioning struma ovarii can have a clinical presentation
similar to that of thyroid toxic adenoma. The under-
lying patho-physiological mechanisms of autonomous
thyroid nodules have been described only recently.
Thyroid toxic adenomas were found to be the conse-
quence of monoclonal proliferation (15). As thyroid
cell proliferation is mainly regulated by TSH and the
way of cAMP, mutations of TSHR and Gs-a protein
were investigated in toxic adenomas (16). In a Belgian
series of 33 thyroid toxic adenomas, TSHR and Gs-a
mutations were found in 82% and 6% of hyperfunc-
tioning tumors respectively (6), as confirmed by other
studies (17, 18). Therefore, we have initially tested
these hypotheses in this struma ovarii, but we were
unable to identify any mutation of TSHR or Gs-a
coding genes. This evidence suggests that (an)other
mutation(s) as yet unknown or (an)other pathophysio-
logical mechanism(s) could be implicated in the
development of the hyperthyroidism caused by
struma ovarii.
The struma ovarii is biochemically and histologically
identical to thyroid tissue. However, it is a benign neo-
plasia that develops during embryogenesis. Is it mono-
clonal in analogy with other teratomas?
Theories on the origin of ovarian teratomas are con-
troversial. Earlier studies showed that teratoma cells are
homozygous for enzyme markers that are heterozygous
in host cells (19), suggesting that teratomas arise from a
single germ cell during the meiotic process. Later studies
showed that distal loci of chromosome arms from
benign ovarian teratomas are heterozygous for genetic
recombination during the long prophase of meiosis
I, whereas centromeric markers are homozygous,
suggesting that teratomas might originate from a
germ cell that had completed the first meiotic division
but failed the second (20, 21). However, other studies
Struma ovarii: clinical and genetic studies 435EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004) 150
www.eje.org
could not detect any homozygous genetic composition
of teratomas while identifying heterozygous centro-
meric markers in a subset of the tumors, suggesting
the possibility of either a postmeiotic or a premeiotic
origin of these tumors (4, 22). Currently, the origin
of teratomas remains debatable, but, generally,
they appear to originate from a single germ cell after a
defective meiosis, with a low incidence of numerical
and/or structural chromosomal aberrations (3, 4).
As already mentioned, the struma ovarii is a rare
ovarian teratoma; thus, genetic studies are very
scant. In this case, we have had the opportunity to
employ the most recent genetic techniques, probably
for the first time.
We evaluated clonality using the AR. The struma
ovarii cells displayed a LOH for the AR, as also con-
firmed by the LOH analysis of chromosome X (LOH at
Xp22.1 –Xq21.32), suggesting the monoclonality of
this tumor and that it derives from a single germ cell.
Furthermore, we analyzed the cytogenetic features of
the struma ovarii, using CGH and ‘conventional’ LOH
analysis to detect possible chromosomal anomalies.
CGH could not detect any chromosomal anomalies,
but several chromosomal alterations were identified
by using LOH, confirming the sensitivity of the LOH
approach. Our results showed multiple loss of regions
in chromosomes 4, 7, 10, 13, 14, 16 and X. Other
cytogenetic analysis of mature ovarian teratomas
showed a very low incidence of numerical and/or struc-
tural aberrations (5–7%) with no consistency or recur-
rency (4, 23, 24). Furthermore, some reports described
chromosomal anomalies in mature ovarian teratomas
that undergo malignant transformation (23, 24).
Some of the chromosomal anomalies described here
have been previously reported in other cases of
mature teratomas. However, some of them were also
described in immature teratomas and in benign
mature teratomas that undergo malignant transform-
ation. Noumoff et al. observed a del(X)(q11) in the
malignant squamous component of an ovarian tera-
toma (24). Loss of heterozygosity on Xq is a common
event in ovarian tumors and contributes to the pro-
gression of the tumor to an undifferentiated stage or
aggressive behavior (25, 26). Chromosome 10 also
seems to be involved in the malignant transformation
of mature ovarian teratomas (23). We report, for the
first time, consistent chromosomal changes on chromo-
some 7. Therefore, our results reveal several structural
chromosomal abnormalities in contrast to normal kar-
yotypes in the majority of benign ovarian teratomas.
Some of the anomalies are consistent with those
described in immature teratomas as well as in some
benign teratomas that undergo malignant transform-
ation. To date, our patient has been followed up for 5
years with no evidence of malignancy. Further studies
are required in order to verify whether specific chromo-
somal aberrations are correlated with the origin of ter-
atomas and with the risk of malignant transformation.
In conclusion, to our knowledge, this is the first report
of thyrotoxic struma ovarii revealed after treatment of a
single thyroid toxic adenoma, illustrating to clinicians
how a tree may hide a forest. This peculiar case allowed
us to gain further insights into the pathophysiology of
this teratoma and of struma ovarii-induced hyperthyr-
oidism. We have shown in this case that 1) struma
ovarii, part of a unique group of tumors, originate
from a single germ cell; 2) albeit benign, they present
several chromosomal abnormalities (mostly deletions);
and 3) struma ovarii-induced hyperthyroidism is likely
to be mediated by mechanisms different from those of
the classical thyroid toxic adenoma.
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